1Halaas JL, Gajowaks KS, Maffd M, et al. The role of necropetide Y in the antiobesity action. Science, 1995,265(28):543- 546.
2Winchester JF,Salsberg JA. Sorbents in the treatrment of renal failure. Minerva Urol Nefrol, 2004,56 (3) : 215 - 221.
3Bray Ca, York DA. The OB protein and the kidney. J Clin Endoerinol Metab, 1997,82(9) :2771 - 2776.
4Zhang Y,Proenda P, Mallei M,et al. Positional cloning of the mourse gene and its human homologue. Nature, 1994,372: 425 - 432.
5Lord GM, Matarese G,Howard JK,et al. Leptin and the kidney. Nature, 1998,394 (6696): 897 - 901.
6Clement K, Vaisse C, Lahlou N, et al. Plasms leptin concentrations are transiently increased in nephrectomized rats. Nature, 1998, 392 (6674) : 398 - 401.
7Young GA, Woodrow G, Kendall S, et al. Increased plasma leptin/fat ratio in patients with chronic renal failure: a cause of malnutrition? Nephrol Dial Transplant, 1997,12(11 ) : 2318 - 2323.
8Heimburger O, Lonnqvist F, Danielsson A, et al. Serum immunoreactive leptin concentration and its relation to the body fat content in chronic renal failure. J Am Soc Nephml, 1997,8(9) : 1423- 1430.
9Wiesholzer M, Harm F, Hauser AC, et al. lnapropriately high plasma leptin levels in obese haemodialysis patients can be reduced by high flux haemodialysis and haemodiafiltration. Clinical Sci(Lond), 1998,94(4) :431 - 435.
9LONDON G M, MARTY C, MARCHAIS S J, et al. Arterial cal- cifications and bonchistomorphometry in end-stage renal dis- ease[ Jl. J Am Soc Nephrol,2004,15 : 1943.
10STENVINKLE P. Inflammatory and atherosclerotic interactions in the depleted uremic patient[ J 1. Blood Purif, 2001,19 (5) : 53-61.
